Biomarker Services
From Biomarker Services & Capabilities
From our proprietary biomarkers, our innovated assays solutions, our unique data analysis platforms and our CDx development capabilities, we offer a comprehensive family of biomarker services that enhance your insight into the tumor microenvironment (TME).
-
Most popular related searches
Services Overview
- Brightplex®
- Immunosign® for pan-cancer immune gene signature analysis
- RNA capabilities for gene expression and transcript sequencing
- DNA sequencing and tumor mutational burden (TMB)
- Data analysis platforms
- CDx development
Immunosign: Powerful Pan-Cancer Immune Gene Signature Analysis
With Immunosign®, clinical researchers can conduct pre- and post-treatment immune monitoring to understand the functional orientation of immune cells and the naturally-occuring intra-tumor immune response.
Immunosign® is available in two predictive and prognostic gene signature panels that provide non-overlapping information on adaptive immunity and immune suppression. The assay is run on the Nanostring platform and can be used with or without the 770 gene nCounter® PanCancer Immune Profiling Panel.
Immunosign® includes categorization of patients into “high” and “low” Immunosign® scores, which are assigned by applying our proprietary algorithms to the Immunosign® gene signatures. The Immunosign® score translates the gene signature analysis into actionable information for patient stratification and deeper insights into treatment impact.
Customer reviews
No reviews were found for Biomarker Services. Be the first to review!